IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo plus PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)

Basit Öğe Kaydı
dc.authorid0000-0002-8417-8628
dc.contributor.authorGrande, E.
dc.contributor.authorGalsky, M.
dc.contributor.authorArranz Arija, J. A.
dc.contributor.authorDe Santis, M.
dc.contributor.authorDavis, I. D.
dc.contributor.authorDe Giorgi, U. F. F.
dc.contributor.authorMencinger, M.
dc.date.accessioned2025-05-10T19:27:51Z
dc.date.issued2019
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description44th Congress of the European-Society-for-Medical-Oncology (ESMO) -- SEP 27-OCT 01, 2019 -- Barcelona, SPAIN
dc.description.abstract[No abstract available]
dc.description.sponsorshipEuropean Soc Med Oncol,Japanese Soc Med Oncol
dc.description.sponsorshipF. Hoffmann-La Roche, Ltd.
dc.description.sponsorshipF. Hoffmann-La Roche, Ltd.
dc.identifier.endpage+
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.scopusqualityQ1
dc.identifier.startpage888
dc.identifier.urihttps://hdl.handle.net/20.500.14730/7092
dc.identifier.volume30
dc.identifier.wosWOS:000491295500138
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherOxford Univ Press
dc.relation.ispartofAnnals of Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.titleIMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo plus PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu